Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Lipotoxicity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lipotoxicity is a metabolic syndrome that results from the accumulation of lipid intermediates in non-adipose tissue, leading to cellular dysfunction and death. The tissues normally affected include the kidneys, liver, heart and skeletal muscle. Lipotoxicity is believed to have a role in heart failure, obesity, and diabetes, and is estimated to affect approximately 25% of the adult American population.
Lipotoxicity Relieving Agent
InactiveUS20080200707A1Preventing and relieving lipotoxicityOrganic active ingredientsOrganic chemistrySide effectPolyunsaturated fatty acid
In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such medical agent is provided. An agent for relieving lipotoxicity which comprises an unsaturated fatty acid containing 18 to 22 carbon atoms and having a degree of unsaturation of 3 to 6 or a derivative thereof as its effective component.
Owner:MOCHIDA PHARM CO LTD
Composition for treating diabetes and containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate
PendingCN106559984AImprove complianceSmall dosePeptide/protein ingredientsMetabolism disorderSide effectInsulin secretion
The present invention relates to a composition for preventing or treating diabetes and containing long-acting insulin analog and long-acting insulin secretion peptide conjugates, and a method for treating diabetes. More specifically, the composition can remarkably improve compliance by inhibiting weight gain caused by the administration of insulin, inhibiting emesis and nausea phenomena caused by the administration of an insulin secretion peptide and reducing the dose of insulin through the concomitant administration of the long-acting analog conjugate and the long-acting insulin secretion peptide conjugate. In addition, the present invention relates to: a pharmaceutical composition for alleviating the side effects of pancreatic beta cells in a patient with diabetes, and containing a long-acting insulin analog conjugate and a long-acting insulin secretion peptide conjugate; and a method for alleviating the side effects of pancreatic beta cells in a patient with diabetes. The method comprises a step of administering the composition. The composition, the pharmaceutical composition and the method are characterized in alleviation of side effects such as pancreatic beta cell dysfunction, pancreatic beta cell reduction, lipotoxicity and glucotoxicity, which are caused by the progression of diabetes.
Owner:HANMI PHARMA
Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
ActiveUS20170143802A1Good treatment effectImprove in duration of efficacyPeptide/protein ingredientsMetabolism disorderSide effectWeight gain
The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide analogue conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.
Owner:HANMI PHARMA
Tartary buckwheat clarified beverage and preparation method thereof
InactiveCN108902593AThe solution is not easy to saveSolve the problem of stomach acid intoleranceFood ingredient functionsBifidobacteriumIsomaltulose
The invention discloses a tartary buckwheat clarified beverage and a preparation method thereof. The tartary buckwheat clarified beverage is prepared from 10-18 parts by weight of tartary buckwheat kernel, 4-10 parts by weight of isomaltulose, 1-6 parts by weight of resistant dextrin, 0.2-0.7 parts of a sour agent, 0.5-1 part by weight of probiotics and the balance of water. Through combination ofthe extract of a tartary buckwheat aqueous solution, isomaltulose and resistant dextrin, the tartary buckwheat clarified beverage has effects of reducing blood fat. Through combination of isomaltulose and the extract of the tartary buckwheat aqueous solution, the tartary buckwheat clarified beverage can inhibit blood sugar increasing and reduce blood sugar. The resistant dextrin can promote the reproduction of bifidobacteria in the intestines, improve the intestinal flora, promote the absorption of flavonoids and isomaltulose in the intestines and stomach, strengthen the effects of the tartary buckwheat clarified beverage and eliminates lipotoxicity.
Owner:金果园老农(北京)食品股份有限公司
Prebiotics-containing formula food for special medicinal use in diabetes and preparation method thereof
InactiveCN108850913ARepair damaged cellsReduce dependenceVitamin food ingredientsInorganic compound food ingredientsAntioxidative stressMomordica
The invention belongs to the technical field of special medicinal food production, and specifically relates to prebiotics-containing formula food for special medicinal use in diabetes and a preparation method thereof. The prebiotics-containing formula food is prepared from the following components in percentage: 15 to 40 percent of yam flour, 11 to 15 percent of whey protein, 10 to 14 percent of resistant dextrin, 8 to 12 percent of walnut powder, 8 to 12 percent of xylitol, 12 to 20 percent of composite peptide powder, 5 to 9 percent of L-arabinose, 5 to 9 percent of inulin, 4 to 8 percent ofxylooliosaccaride powder 95, 0.080 to 0.1 percent of decavitamin, 0.4 to 0.45 percent of composite minerals, 2 to 6 percent of a momordica charantia extract and 1 to 5 percent of a herba gynostemmatis extract. The prebiotics-containing formula food disclosed by the invention not only is capable of effectively reducing blood glucose, but also has the functions of increasing the anti-oxidative stress ability of diabetic mice and reducing the lipotoxicity, and the function of protecting pancreatic tissues can be achieved.
Owner:SHANDONG LONGLIVE BIO TECH CO LTD
Method and compounds for modulating insulin production
InactiveUS20090137543A1High expressionIncrease productionCompound screeningBiocideProgenitorScreening method
The present invention provides screening methods for the detection of agents that affect various aspects of β-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect β-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity.
Owner:BURNHAM INST FOR MEDICAL RES +1
Cell-metabonomics-based difference metabolite metabolic pathway of rubusoside lipotoxicity resistance and research method
InactiveCN108414635AComprehensive evaluationEffective evaluationComponent separationStudy methodsInsulin secreting adenoma
The invention discloses a cell-metabonomics-based difference metabolite metabolic pathway of rubusoside lipotoxicity resistance and a research method, relates to research methods of natural plant drugeffective component action mechanisms, and aims to solve the problem that an existing single pharmacology method cannot systematically and comprehensively evaluate the natural plant drug effective component action mechanisms. The method includes the steps of firstly, using ultrahigh performance liquid chromatography-tandem mass spectrum technology to detect and analyze palmitic acid induced rateinsulin oncocyte and rubusoside intervened intracellular metabolites; secondly, screening 12 potential lipotoxicity related difference metabolites, and identifying; thirdly, screening four metabolic pathways of the rubusoside lipotoxicity resistance and related enzymes and genes on the pathways, and analyzing. The method can comprehensively, efficiently and fast evaluate the rubusoside lipotoxicity resistance action mechanism from cell level in a bias-free manner, and a demonstrative basis is provided for natural plant drug effective component cell metabonomics and action mechanism illustration.
Owner:GUANGXI MEDICAL UNIVERSITY
Means and method for treating lipotoxicity and other metabolically related phenomena
A method for treating symptoms of a lipotoxicity-related phenomenon includes introducing into a patient a therapeutically effective synergistic amount of a phenomenon-inhibiting cocktail of a polyphenol (P), thiol antioxidant (To) and ascorbic acid (A) to reduce intracellular reactive oxygen species (ROS) and / or increase intracellular nitrite (NO), so that reduction of such phenomenon is at least 30% greater than the reduction of such phenomenon provided by separate administration of each of P, To and A.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Methods of use of islet cells
Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.
Owner:CEDARS SINAI MEDICAL CENT
Triacylglycerol-deficient fission yeast and its uses
InactiveUS20070128605A1Easy to useInhibit lipoapoptosis and lipotoxicityFungiMicrobiological testing/measurementBiotechnologyApoptosis
A fission yeast having non-functional dga1 and plh1 genes, which is incapable of synthesizing triacylglycerols, is disclosed. The fission yeast is susceptible to lipotoxicity including lipoapoptosis, and is useful for screening of compounds that inhibit or prevent lipotoxicity or lipoapoptosis. The fission yeast strain may be transformed to express a mammalian enzyme involved in triacylglycerol synthesis, and therefore is also useful for screening of compounds that inhibit or prevent triacylglycerol synthesis, which activity is conferred by the mammalian enzyme.
Owner:NAT UNIV OF SINGAPORE
Application of pharmaceutical composition in preparing medicament for treating type 2 diabetes mellitus due to lipotoxicity by reducing SREBP1-C
The invention belongs to the medical field, and relates to an application of a pharmaceutical composition in preparing a medicament for reducing SREBP1-c, wherein the pharmaceutical composition is prepared by the following traditional Chinese medicine raw materials by weight: 540 parts of trichosanthin, 10-30 parts of radix bupleuri, 3-15 parts of citrus aurantium, 1-6 parts of raw rhubarb, 1-12 parts of pinellia tuberifera, 3-15 parts of radix scutellariae, 1-12 parts of coptis, 3-15 parts of white peony roots, and 5-20 parts of dark plums.
Owner:北京中一堂科技有限公司
Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
ActiveUS9512092B2Effective stressCompound screeningApoptosis detectionOxidative stressChaperone-mediated autophagy
Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and / or antagonizing activity of retinoic acid receptor alpha (RARα) in subjects in need thereof.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
ActiveUS10159715B2Good treatment effectImprove efficacyPeptide/protein ingredientsMetabolism disorderSide effectInsulin humulin
The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analog conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analog conjugate and a long-acting insulinotropic peptide analog conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.
Owner:HANMI PHARMA
Method for modulating insulin production
InactiveUS8168391B2High expressionIncrease productionBiocideCompound screeningProgenitorScreening method
The present invention provides screening methods for the detection of agents that affect various aspects of β-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect β-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity.
Owner:BURNHAM INST FOR MEDICAL RES +1
Application of oxymatrine in reducing epidermal cell death caused by lipotoxicity of psoriasis patient
PendingCN112843056AAltered skin metabolism homeostasisOrganic active ingredientsDermatological disorderPsoriasis patientLipidome
Owner:GENERAL HOSPITAL OF NINGXIA MEDICAL UNIV
Lipotoxicity relieving agent
In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such medical agent is provided. An agent for relieving lipotoxicity which comprises an unsaturated fatty acid containing 18 to 22 carbon atoms and having a degree of unsaturation of 3 to 6 or a derivative thereof as its effective component.
Owner:AMARIN PHARMA IRELAND
Food product for regulating lipid metabolites and methods
The present invention relates to methods of determining the levels of endogenous margaric acid before and after a meal in a companion animal, wherein the meal is a pet foodstuff having a particular protein to fat ratio, which is useful in increasing the endogenous levels of margaric acid post-prandially and having the beneficial effects as described herein. The pet foodstuff comprises a ratio of protein to fat of 1:0.27 to 1:0.63 on a gram:gram as fed or dry matter basis. The invention also relates to methods of determining levels of lipid metabolites, such as palmitic acid, diacylglycerol (DAG), triacylglycerols (TAGs) and ceramides before and after a meal in a companion animal, wherein the meal is a pet foodstuff having a particular protein-fat ratio, which is useful in controlling, regulating and stabilizing lipid metabolites post-prandially to prevent and / or reduce lipotoxicity in the companion animal.
Owner:MARS INC
Modulation of GLUT4 Gene Promoter activity BY AHNAK
InactiveUS20110015123A1Reduce depressionOrganic active ingredientsPeptide/protein ingredientsPromoter activityGLUT4
Owner:TECHNION RES & DEV FOUND LTD
Modulation of glut4 gene promoter activity by ahnak
Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and / or alleviation of insulin resistance associated with obesity, lipotoxicity, hypertension, metabolic syndrome and type 2 diabetes. Preferred agents are double-stranded siRNAs.
Owner:TECHNION RES & DEV FOUND LTD
Application of paeonol in preparation of medicine for treating obesity and lipotoxic cardiomyopathy
PendingCN114306294AReduce weightReduce obesityMetabolism disorderKetone active ingredientsGlycolipid metabolismGlycolipid
The invention belongs to a novel application of paeonol, and particularly relates to an application of paeonol in preparation of medicines for treating obesity and lipotoxic cardiomyopathy. In a model of treating mouse obesity by paeonol, through animal characterization and oil red o staining of rat primary myocardial cells, the effect of paeonol in glycolipid metabolism change and heart lipid metabolism disorder caused in a mouse obesity model fed with high fat diet is researched. The results show that paeonol can alleviate glycolipid metabolism change and heart lipid toxicity caused by obesity induced by high fat diet. Paeonol may become a potential effective treatment method for heart lipotoxicity caused by obesity.
Owner:CHINA PHARM UNIV
New application of palmitic acid as methylselenic acid anti-hepatoma sensitizer
ActiveCN112274503AGood prevention effectEnhanced apoptosisDigestive systemAntineoplastic agentsMethylselenic acidPharmaceutical drug
The invention provides a new application of palmitic acid as a methylselenic acid anti-hepatoma sensitizer. The invention provides a new application of palmitic acid and methylselenic acid in treatment of liver cancer. The invention discloses that palmitic acid has the effect of enhancing hepatoma cell apoptosis induced by methylselenic acid, has a good synergistic effect on anti-hepatoma treatment of methylselenic acid, and methylselenic acid has a good prevention effect on possible potential lipotoxicity of palmitic acid. The invention provides a scientific basis for developing anti-hepatomadrugs based on palmitic acid and methylselenic acid, and has important application value.
Owner:CHINA AGRI UNIV
Compounds, compositions and corresponding uses for preventing and/or treating of dyslipidemia
ActiveUS9821000B2Suppress high blood pressureEffect is exertedMetabolism disorderDigestive systemDyslipidemiaObstructive Pulmonary Diseases
Owner:CENT NAT DE LA RECH SCI (C N R S) +1
Application of rice bran active peptide in prevention or treatment of lipotoxicity related diseases
PendingCN114558106AEasy to interveneGood treatment effectPeptide/protein ingredientsMetabolism disorderBiotechnologyDisease
Owner:长沙飞创生物技术有限责任公司
Application of anethol trithione in preparation of medicine for preventing and/or treating toxic fatty acid-caused lipotoxicity of body cells
PendingCN111195248AIncreased beta oxidationEasy to transportOrganic active ingredientsNervous disorderLiver and kidneyFat Droplet
It is found that anethol trithione (H2S donor) can significantly reduce ACC1 and FAS expression and SCD1 expression, up-regulate FADS1 and FADS2 and inhibit de novo synthesis of toxic saturated fattyacid (palmitic acid), inhibit the synthesis of oleic acid, promote the desaturation of fatty acid and adjust the proportion of n-3 / n-6 polyunsaturated fatty acid under the condition of high-fat diet.Meanwhile, PAQR3 is inhibited to promote peroxidase body oxidation of lipid and degradation of LDL; in addition, the expression quantity of RTN3 can be reduced, so that the overexpression of SREPB1c is reduced, and the formation of liver cell fat droplets is reduced; the reduced expression of FATP2, FATP4, FATP5 and L-FABP can be up-regulated, which indicates that the drug enhances fatty acid uptake of hepatocytes and promotes transport of the hepatocytes; it is particularly noticed that anethol trithione can remarkably increase the expression quantity of Mitofusin 1, Mitofusin 2 and CPT1a, mitochondrial fusion is promoted, beta-oxidation of fatty acid is enhanced, and the anethol trithione is widely applied to damage of toxic fatty acid to organs such as heart, brain, liver and kidney.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Foodstuffs and methods for modulating lipid metabolites
The present invention relates to a method for determining preprandial and postprandial endogenous heptadecanoic acid levels in a companion animal, wherein the meal is a pet food having a specific protein to fat ratio that is effective in increasing postprandial endogenous heptadecanoic acid levels Useful and have benefits as described herein. The pet food comprises a protein to fat ratio of 1:0.27 to 1:0.63 on a gram:gram basis on a feed or dry matter basis. The present invention also relates to methods for determining the levels of lipid metabolites such as palmitic acid, diacylglycerol (DAG), triacylglycerol (TAG) and ceramide before and after a meal in a companion animal, wherein the meal is a combination of specific proteins and fats A specific pet food that has an effect on postprandial control, regulation and stabilization of lipid metabolites to prevent and / or reduce lipotoxicity in companion animals.
Owner:MARS INC
Synergistic Anti-oxidant treatment for lipotoxicity and other metabolically related phenomena
InactiveUS20100210718A1Lipotoxic effectIncrease probabilityBiocideAnimal cellsCoronary heart diseaseAnti oxidant
A method for ameliorating, reducing, and / or preventing lipotoxicity-induced metabolic dysfunction in at least one cell is disclosed, said method comprising a step of contacting said at least one cell with a therapeutically effective amount of a synergistic anti-lipotoxicity cocktail, said cocktail comprising N-acetylcysteine, ascorbic acid, and resveratrol. Also disclosed is a method for treating at least one lipotoxicity-related metabolic disorder chosen from the group comprising (a) metabolic syndrome; (b) non-alcoholic steatohepatitis; (c) obesity; and (d) coronary heart disease, said method comprising the step of administering to a patient a therapeutically effective amount of an anti-lipotoxicity cocktail, said cocktail comprising N-acetylcysteine, ascorbic acid, and resveratrol. Finally, a composition for treating the effects of lipotoxicity, containing a synergistic combination of N-acetylcysteine, ascorbic acid, and resveratrol is disclosed.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
New application of palmitic acid as anti-hepatocarcinoma sensitizer of methylselenic acid
ActiveCN112274503BGood prevention effectEnhanced apoptosisDigestive systemAnhydride/acid/halide active ingredientsMethylselenic acidApoptosis
The invention provides a new application of palmitic acid as an anti-hepatoma sensitizer of methyl selenic acid. The invention provides a new application of combining palmitic acid and methyl selenic acid in treating liver cancer. The present invention reveals that palmitic acid has the effect of enhancing the apoptosis of liver cancer cells induced by methyl selenic acid, has a good synergistic effect on the anti-liver cancer treatment of methyl selenic acid, and that methyl selenic acid may have a potential lipotoxic effect on palmitic acid Has a good preventive effect. The invention provides a scientific basis for developing anti-liver cancer drugs based on palmitic acid and methyl selenic acid, and has great application value.
Owner:CHINA AGRI UNIV
Lipotoxicity relieving agent
ActiveUS20090209644A1Preventing and relieving lipotoxicityBiocideMetabolism disorderSide effectToxicity
In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such medical agent is provided. An agent for relieving lipotoxicity which comprises an unsaturated fatty acid containing 18 to 22 carbon atoms and having a degree of unsaturation of 3 to 6 or a derivative thereof as its effective component.
Owner:AMARIN PHARMA IRELAND
Compounds, compositions and corresponding uses for preventing and/or treating of dyslipidemia
ActiveUS20160287542A1Suppress high blood pressureEffect is exertedOrganic active ingredientsMetabolism disorderDyslipidemiaObstructive Pulmonary Diseases
The present invention relates to the field of medicine. It relates more particularly to the use of compounds to prevent and / or treat lipotoxicity in a subject, especially lipotoxicity by hypoxia. The invention relates more particularly to compositions, especially pharmaceuticals compositions and nutritional supplements or complements comprising such compounds as well as their use to prevent and / or treat lipotoxicity, especially lipotoxicity by hypoxia. The compounds and compositions of the invention can especially be advantageously used to prevent and / or treat a pathology from among pulmonary pathologies, especially cystic fibrosis or a chronic obstructive pulmonary disease.
Owner:CENT NAT DE LA RECHERCHE SCI +1
Triacylglycerol-deficient fission yeast and its uses
InactiveUS7479374B2Easy to useInhibit lipoapoptosis and lipotoxicityFungiMicrobiological testing/measurementBiotechnologyYeast
A fission yeast having non-functional dga1 and plh1 genes, which is incapable of synthesizing triacylglycerols, is disclosed. The fission yeast is susceptible to lipotoxicity including lipoapoptosis, and is useful for screening of compounds that inhibit or prevent lipotoxicity or lipoapoptosis. The fission yeast strain may be transformed to express a mammalian enzyme involved in triacylglycerol synthesis, and therefore is also useful for screening of compounds that inhibit or prevent triacylglycerol synthesis, which activity is conferred by the mammalian enzyme.
Owner:NAT UNIV OF SINGAPORE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com